Home > News > Introgen applies to market Advexin in Europe
November 13th, 2007
Introgen applies to market Advexin in Europe
Abstract:
Introgen Therapeutics Inc. and its subsidiary, Gendux Molecular Ltd., have submitted a marketing authorization application to the European Medicines Agency for Advexin, a tumor suppressor therapy for use in the treatment of a type of cancer known as Li-Fraumeni Syndrome.
Austin-based Introgen (NASDAQ: INGN) has offices housing a clinical and regulatory development staff of about 70 in the Texas Medical Center plus a manufacturing facility nearby.
A year ago, the biotech company obtained an exclusive worldwide license to a portfolio of patents from The University of Texas M.D. Anderson Cancer Center, along with agreements to commercialize products based on the licensed technologies. Those patents are focused on the delivery of biologically active proteins, polypeptides and peptides on the nanoparticle level.
Source:
bizjournals.com
Bookmark:
Nanomedicine
European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Iranian Scientists Produce Dynamometer for Nanoparticles, Biocells June 15th, 2013
Discovery of new material state counterintuitive to laws of physics June 14th, 2013
Announcements
An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013
Polymer-coated catalyst protects "artificial leaf" June 17th, 2013
Efficient and inexpensive: Researchers develop catalyst material for fuel cells: Platinum-nickel nano-octahedra save 90 percent platinum June 17th, 2013
AXEON Acquires Assets of Leading Reverse Osmosis Systems Manufacturer June 17th, 2013